Table 4.
Attrition by baseline characteristics
| Baseline characteristics | n | Attrition % (95% CI) |
|---|---|---|
| Sex | ||
| Female | 4831 | 18.4 (17.3–19.5)* |
| Male | 2827 | 21.8 (20.2–23.3) |
| Age group (years) | ||
| 15–19 | 109 | 28.4 (20.0–36.9) |
| 20–24 | 296 | 26.4 (21.3–31.4) |
| 25–29 | 881 | 20.2 (17.6–22.9) |
| 30–54 | 5881 | 19.0 (18.0–20.0)* |
| ≥55 | 491 | 19.6 (16.0–23.1) |
| Marital status | ||
| Single | 1744 | 21.9 (20.0–23.8) |
| Married | 4294 | 18.4 (17.2–19.5)* |
| Divorced/separated | 591 | 23.5 (20.1–26.9) |
| Widowed | 774 | 18.2 (15.5–20.9) |
| Not documented | 255 | 20.4 (15.4–25.3) |
| Residence | ||
| Rural | 1086 | 17.3 (15.1–19.6)* |
| Urban | 5946 | 19.6 (18.6–20.6) |
| Not documented | 626 | 24.0 (20.6–27.3) |
| Care entry point | ||
| VCT | 3240 | 18.5 (17.2–19.9)* |
| PMTCT | 1195 | 18.2 (16.0–20.3) |
| TB | 671 | 17.6 (14.7–20.5) |
| In-patient | 702 | 23.4 (20.2–26.5) |
| Other facilities | 291 | 27.1 (22.0–32.3) |
| Other sources | 919 | 17.2 (14.8–19.6) |
| Not documented | 640 | 25.8 (22.4–29.2) |
| Linked to ART after HIV diagnosis | ||
| 3 months | ||
| Within 3 months | 1943 | 18.0 (16.3–19.7)* |
| After 3 months | 3181 | 18.6 (17.2–19.9) |
| 6 months | ||
| Within 6 months | 2300 | 18.6 (17.0–20.2)* |
| After 6 months | 2824 | 18.2 (16.7–19.6) |
| 12 months | ||
| Within 12 months | 2828 | 17.9 (16.5–19.3)* |
| After 12 months | 2296 | 18.9 (17.3–20.5) |
| HIV diagnosis date not documented | 2534 | 22.1 (20.5–23.8) |
| Disease stage | ||
| WHO stages 1 and 2 | 3087 | 16.6 (15.3–17.9)* |
| WHO stages 3 and 4 | 2931 | 23.2 (21.7–24.7) |
| Not documented | 1640 | 18.8 (16.9–20.7) |
| CD4 count | ||
| 0–50 | 1250 | 21.8 (19.5–24.0) |
| 51–100 | 977 | 19.5 (17.1–22.0) |
| 101–250 | 513 | 17.0 (13.7–20.2) |
| 251–350 | 793 | 17.3 (14.6–19.9)* |
| 351–500 | 658 | 13.7 (11.1–16.3) |
| >500 | 592 | 15.5 (12.6–18.5) |
| Not documented | 2875 | 22.0 (20.5–23.5) |
| OIs | ||
| TB | ||
| No | 6877 | 19.2 (18.2–20.1)* |
| Yes | 781 | 23.4 (20.5–26.4) |
| PCP | ||
| No | 7387 | 19.6 (18.7–20.5)* |
| Yes | 271 | 20.3 (15.5–25.1) |
| Cryptococcal disease | ||
| No | 7607 | 19.6 (18.7–20.5)* |
| Yes | 51 | 15.7 (5.7–25.7) |
| Oral candidiasis | ||
| No | 7424 | 19.6 (18.7–20.5)* |
| Yes | 234 | 20.1 (15.0–25.2) |
| Esophageal candidiasis | ||
| No | 7631 | 19.6 (18.7–20.5)* |
| Yes | 27 | 22.2 (6.5–37.9) |
| Kaposi’s sarcoma | ||
| No | 7583 | 19.6 (18.7–20.5)* |
| Yes | 75 | 20.0 (10.9–29.1) |
| Other OIs | ||
| No | 5609 | 19.1 (18.1–20.1)* |
| Yes | 2049 | 21.0 (19.3–22.8) |
| Any OI | ||
| No | 4901 | 18.9 (17.8–20.0)* |
| Yes | 2757 | 20.9 (19.4–22.4) |
Notes: The values in bold font are significant by virtue of the fact that the confidence intervals do not overlap with those of the respective reference categories. Reference categories are indicated by the * symbol.
Abbreviations: ART, antiretroviral therapy; OI, opportunistic infection; PCP, pneumocystis pneumonia; PMTCT, prevention of mother-to-child transmission; TB, tuberculosis; VCT, voluntary counseling and testing; WHO, World Health Organization.